ReviewClinical pharmacology and therapeutics2010
Transporters for drug delivery and as drug targets in parasitic protozoa.
Review in Clinical pharmacology and therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- Diversity, expression, and structural modeling of sugar transporters inFrontiers in cellular and infection microbiology · 2025Article
- NAT/NCS2-hound: a webserver for the detection and evolutionary classification of prokaryotic and eukaryotic nucleobase-cation symporters of the NAT/NCS2 family.GigaScience · 2018Article
- TryTransDB: A web-based resource for transport proteins in Trypanosomatidae.Scientific reports · 2018Article
- Attolitre-sized lipid bilayer chamber array for rapid detection of single transporters.Scientific reports · 2015Article
- The effect of tunicamycin on the glucose uptake, growth, and cellular adhesion in the protozoan parasite Crithidia fasciculata.Current microbiology · 2014Article
- Article
- Insights to the evolution of Nucleobase-Ascorbate Transporters (NAT/NCS2 family) from the Cys-scanning analysis of xanthine permease XanQ.International journal of biochemistry and molecular biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Parasitic protozoa cause devastating diseases across large regions of the globe, but a lack of economic incentives has resulted in the limited development of drugs against these "neglected diseases." Transporters expressed in the plasma membranes of these parasites offer potential for the development of new drugs. These permeases could be employed in two distinct strategies for drug development: (i) targeting selective delivery of drugs to the parasite and (ii) developing drugs that inhibit essential parasite permeases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.